SNH-118110
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SNH-118110 in Patients With Advanced Solid Tumors
Sponsor study identifier
interventional
240
1 country
1
Study Start
June 26, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 26, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 26, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is a multicenter, open-label, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SNH-118110 administered orally. The study consists of a dose-escalation phase and a dose-expansion phase.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 26, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 11, 2026
Actual (reported)June 16, 2026
Actual (reported)June 26, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 26, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 26, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Safety evaluation
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
Up to approximately 2 years
Maximum tolerated dose (MTD) or maximum administered dose (MAD)
Determination of the MTD or MAD of oral SNH-118110 by the number of participants who experience a dose limiting toxicity (DLT)
Cycle 1 (up to 21 days)
The maximum concentration (Cmax)
Cycle 1 day 1 through cycle 2 day 1 (cycle= 21 days)
Time of the maximum concentration (Tmax)
Cycle 1 day 1 through cycle 2 day 1 (cycle= 21 days)
Area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC0-t)
Cycle 1 day 1 through cycle 2 day 1 (cycle= 21 days)
Elimination half-life (t1/2)
Cycle 1 day 1 through cycle 2 day 1 (cycle= 21 days)
Objective response rate (ORR)
Up to approximately 2 years
Dose escalation: Multiple doses of SNH-118110 Dose expansion: MTD/MAD/recommended expansion dose
Participants will continue treatment until progression of disease or the end of the study.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The East Hospital Affiliated to Tongji University, Shanghai
Shanghai, Shanghai Municipality, 200120, China
First Submitted
June 11, 2026
First Posted
June 16, 2026
Study Start
June 26, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 26, 2027
EstimatedContact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 26, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
June 16, 2026
Record last verified: 2026-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: